Beam Therapeutics Inc. (BEAM)
Nasdaq: BEAM · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2018
Who owns Beam Therapeutics Inc.
As filed with the SECHolders of 5% or more
7
Fmr LLC holds 12.6% of COMMON STOCK, as its SCHEDULE 13G/A filed Feb 5, 2026 says.
Directors and officers
12
report now, of 17 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 7 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Feb 5, 2026 · COMMON STOCK · 13.6% in Nov 5, 2025
Farallon Capital Management, L.L.C.
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock, par value $0.01 per share (the "Shares")
Dapice Joshua J.
SCHEDULE 13G/A · filed Feb 5, 2026 · Common Stock, par value $0.01 per share (the "Shares") · 9.99% in May 13, 2025
ARK Investment Management LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock · 12.3% in Feb 3, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 17, 2025 · Common Stock
State Street Corporation
SCHEDULE 13G · filed Feb 9, 2026 · COMMON STOCK
Vanguard Capital Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
Robert Nelsen
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock par value $0.01 per share · reported falling below 5%, from 5.6% in Feb 14, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What BEAM reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Orbital Therapeutics, Inc
An investee · investee · invested in, named in the 10-K filed Feb 24, 2026
Guide Therapeutics Incorporated
A company bought · acquisition · owns, named in the 10-K filed Feb 24, 2026
Insider tradesForm 4
29sales
0purchases
29sales on a scheduled plan
6people selling
$9.7Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 16, 2025 to Oct 16, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 16, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 27 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Fmr LLC | 10% owner | 3 | $10.1M | 0 | 0 | $0 |
| Evans John M. | CEO | 13 | $6.2M | 13 | 0 | $0 |
| Ciaramella Giuseppe | President | 2 | $1.4M | 2 | 0 | $0 |
| Bellon Christine | Chief Legal Officer | 6 | $900,000 | 6 | 0 | $0 |
| Simon Amy | Chief Medical Officer | 3 | $600,000 | 3 | 0 | $0 |
| Cavanagh Bethany J | SVP, Finance and Treasurer | 4 | $400,000 | 4 | 0 | $0 |
| Emany Sravan Kumar | Chief Financial Officer | 1 | $200,000 | 1 | 0 | $0 |